Research ExplorerPublicationsPharmacokinetics of meropenem during advanced organ support ...

Pharmacokinetics of meropenem during advanced organ support (ADVOS®) and continuous renal replacement therapy

Standard

Pharmacokinetics of meropenem during advanced organ support (ADVOS®) and continuous renal replacement therapy. / König, Christina; Kluge, Stefan; Fuhrmann, Valentin; Jarczak, Dominik.

In: INT J ARTIF ORGANS, Vol. 44, No. 10, 10.2021, p. 783-786.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

König, C, Kluge, S, Fuhrmann, V & Jarczak, D 2021, 'Pharmacokinetics of meropenem during advanced organ support (ADVOS®) and continuous renal replacement therapy', INT J ARTIF ORGANS, vol. 44, no. 10, pp. 783-786. https://doi.org/10.1177/03913988211021101

APA

König, C., Kluge, S., Fuhrmann, V., & Jarczak, D. (2021). Pharmacokinetics of meropenem during advanced organ support (ADVOS®) and continuous renal replacement therapy. INT J ARTIF ORGANS, 44(10), 783-786. https://doi.org/10.1177/03913988211021101

Vancouver

König C, Kluge S, Fuhrmann V, Jarczak D. Pharmacokinetics of meropenem during advanced organ support (ADVOS®) and continuous renal replacement therapy. INT J ARTIF ORGANS. 2021 Oct;44(10):783-786. https://doi.org/10.1177/03913988211021101

Bibtex

@article{1404958201cb4cc4a6571311d2732ee0,
title = "Pharmacokinetics of meropenem during advanced organ support (ADVOS{\textregistered}) and continuous renal replacement therapy",
abstract = "The advanced organ support (ADVOS) system allows to eliminate water-soluble as well as protein-bound molecules. Despite its clinical features, to date nothing is known about the elimination of clinically relevant drugs such as antiinfectives. Therefore, we report a case treated with ADVOS, continuous renal replacement therapy (CRRT), and meropenem (1 g 8-hourly) for empiric sepsis therapy monitored by meropenem drug levels. ADVOS showed more efficient elimination of meropenem compared to CRRT which has to be considered when evaluating dosing regimens.",
author = "Christina K{\"o}nig and Stefan Kluge and Valentin Fuhrmann and Dominik Jarczak",
year = "2021",
month = oct,
doi = "10.1177/03913988211021101",
language = "English",
volume = "44",
pages = "783--786",
journal = "INT J ARTIF ORGANS",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "10",

}

RIS

TY - JOUR

T1 - Pharmacokinetics of meropenem during advanced organ support (ADVOS®) and continuous renal replacement therapy

AU - König, Christina

AU - Kluge, Stefan

AU - Fuhrmann, Valentin

AU - Jarczak, Dominik

PY - 2021/10

Y1 - 2021/10

N2 - The advanced organ support (ADVOS) system allows to eliminate water-soluble as well as protein-bound molecules. Despite its clinical features, to date nothing is known about the elimination of clinically relevant drugs such as antiinfectives. Therefore, we report a case treated with ADVOS, continuous renal replacement therapy (CRRT), and meropenem (1 g 8-hourly) for empiric sepsis therapy monitored by meropenem drug levels. ADVOS showed more efficient elimination of meropenem compared to CRRT which has to be considered when evaluating dosing regimens.

AB - The advanced organ support (ADVOS) system allows to eliminate water-soluble as well as protein-bound molecules. Despite its clinical features, to date nothing is known about the elimination of clinically relevant drugs such as antiinfectives. Therefore, we report a case treated with ADVOS, continuous renal replacement therapy (CRRT), and meropenem (1 g 8-hourly) for empiric sepsis therapy monitored by meropenem drug levels. ADVOS showed more efficient elimination of meropenem compared to CRRT which has to be considered when evaluating dosing regimens.

U2 - 10.1177/03913988211021101

DO - 10.1177/03913988211021101

M3 - SCORING: Journal article

C2 - 34144656

VL - 44

SP - 783

EP - 786

JO - INT J ARTIF ORGANS

JF - INT J ARTIF ORGANS

SN - 0391-3988

IS - 10

ER -